3D Molecular Sciences shortlisted for Business Weekly East of England Business Awards

28 January 2003, Cambridge, UK… 3D Molecular Sciences has been shortlisted for the Innovation in Biotech category in the Business Weekly East of England Business Awards. The company was invited by Business Weekly to participate in the annual awards on the basis of having developed a new, innovative BioMEMS technology with applications in biotech and pharma for multiplexing. 

3D Molecular Sciences has designed a new system for performing large-scale simultaneous and parallel bioassay analysis using individually coded particles compatible with a diverse range of assays including nucleic acids and cytokines. The Company’s technology platform offers an inexpensive and flexible tool to the pharmaceutical, biotech and clinical diagnostic industries that allows for a superior volume of tests, a scaleable capability and multiplexing of samples. It has the potential to screen for gene-linked diseases such as cancer, Alzheimer's, obesity and cystic fibrosis. It can also offer great possibilities in compound library screening, environmental monitoring and in anti-terrorism systems.

Dr Elizabeth Hill, 3D Molecular Sciences’ CEO, said, “We are delighted to have been selected for this leading regional business to business annual competition. 3D Molecular Sciences has been shortlisted for the final awards following a series of stringent selection procedures, a great achievement in itself as this year's awards have attracted record number of applicants. This positions the Company as a clear leader in its field globally and a recognised innovator within the Cambridge region.”

This year's Business Weekly East of England Business Awards are sponsored by, among others, the London Stock Exchange, the East of England Development Agency, and a leading international law firm Mills & Reeve. The winners of the awards will be announced 25 February.

Ends

Notes for editors:
1. 3D MOLECULAR SCIENCES LTD was incorporated in October 2001 as a spin out from the Generics Group to commercialise a particle-based assay platform designed for large scale genomic and proteomic analysis, as well as diagnostic and combinatorial chemistry. The company operates from premises at Harston, Cambridgeshire, UK. The company has secured funding of £0.5m ($0.7m) from both the Generics Group and the InterIkea Fund, a fund managed by Generics Asset Management Ltd.
For more information, visit www.3d-molecularsciences.com 

2. THE GENERICS GROUP (GENERICS) is a leading integrated technology consulting, development and investment organisation, with an international reputation for successfully commercialising emerging science and technology.

Generics invests in and develops technologies that underpin the future of the widest range of industries. Its key areas of expertise include: engineering, materials, telecommunications, life sciences, business innovation and electronics.

Generics’ facilities include state-of-the-art laboratories and are located in Cambridge, UK; in Zurich, Switzerland; in Stockholm, Sweden; and in Boston and Baltimore in the USA. Generics has over 300 employees, of which more than half are high-calibre technology professionals.

News Release
For further information please contact:
Commercial/investor enquiries:
Dr Elizabeth Hill, CEO
Tel: +44 (0) 1223 875280
Mobile: +44 (0)7769 704693
E-mail: elizabeth.hill@3d-molecularsciences.com

Media enquiries:
Sue Charles, Northbank Communications
Tel: +44 (0)20 7321 3872
Mobile: +44 (0)7968 726585
E-mail: s.charles@northbankcommunications.com